logo
Twitter
Discord
Email
logo
Pharming Group N.V.

Pharming Group N.V.

NASDAQ•PHAR
CEO: Dr. Sijmen de Vries M.B.A., M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-12-23
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Contact Information
Darwinweg 24, Leiden, 2333 CR, Netherlands
31-71-524-7400
www.pharming.com
Market Cap
$1.22B
P/E (TTM)
3122.0
42.1
Dividend Yield
--
52W High
$18.12
52W Low
$7.50
52W Range
97%
Rank51Top 58.4%
3.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$97.29M+29.61%
4-Quarter Trend

EPS

$0.11-787.50%
4-Quarter Trend

FCF

$29.94M+220.63%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Revenue Increased 21.1% Revenue increased 21.1% to $297.2M, driven by Joenja® sales growth to $45.0M worldwide.
Adjusted EBITDA Reached $11.5M Adjusted EBITDA reached $11.5M in 2024, up from $6.2M in 2023, showing core profitability trend.
Joenja UK Authorization Secured Secured UK marketing authorization for Joenja® in September 2024; regulatory filing anticipated in Japan mid-2025.
Strong Cash and Securities Total cash and marketable securities stood at $167.9M as of December 31, 2024, supporting operations.

Risk Factors

RUCONEST® Market Competition RUCONEST® faces intense competition in HAE acute market; prophylactic therapies increasingly reduce demand for acute use.
Internal Control Material Weaknesses Material weaknesses in internal controls over corporate tax and complex transactions persist into 2024, requiring remediation.
High Customer Revenue Concentration Two US customers accounted for 77% of 2024 net revenues, posing significant concentration risk to revenue stability.
New Drug Safety Concerns Newly approved drug Joenja® could face adverse safety findings impacting market acceptance and future sales potential.

Outlook

Pediatric Leniolisib Submission Planned Plan US submission for pediatric APDS indication in second half of 2025, supporting global label expansion efforts.
Pipeline Expansion Priorities Investing in leniolisib for broader PIDs and advancing KL1333 for mitochondrial disease pipeline opportunities.
Manufacturing Commitments Remain Total future manufacturing commitments for RUCONEST® and Joenja® approximate $41.6M for 2025.
Increased Operating Expenses Expected Expect increased R&D and SG&A expenses in 2025 due to Joenja® launch preparations and pipeline investment.

Peer Comparison

Revenue (TTM)

Pharming Group N.V.PHAR
$362.27M
+26.4%
Maravai LifeSciences Holdings, Inc.MRVI
$192.28M
-30.6%
AnaptysBio, Inc.ANAB
$169.47M
+196.4%

Gross Margin (Latest Quarter)

ProKidney Corp.PROK
100.0%
+0.0pp
Xencor, Inc.XNCR
93.9%
+11.7pp
Pharming Group N.V.PHAR
92.7%
+1.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANAB$1.24B-14.8-1101.2%4.1%
PHAR$1.22B3122.00.2%27.6%
XNCR$1.18B-6.9-26.7%24.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.6%
Moderate Growth
4Q Net Income CAGR
38.2%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Mar 12, 2026
|
EPS:$0.18
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 3, 2025|
    Revenue: $321.51M+21.1%
    |
    EPS: $-0.18-17.2%
    Miss

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 4, 2024|
    Revenue: $245.32M+19.3%
    |
    EPS: $-0.14-187.3%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 5, 2023|
    Revenue: $205.62M+3.4%
    |
    EPS: $0.17-17.0%
    Beat

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Apr 6, 2022|
    Revenue: $224.50M-6.3%
    |
    EPS: $0.24-57.7%
    Miss

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Apr 7, 2021|
    Revenue: $260.49M+12.0%
    |
    EPS: $0.52-9.0%
    Miss